cAMP-specific 3',5'-cyclic phosphodiesterase 4D isoform 3 (PDE4D3)

cAMP-specific 3',5'-cyclic phosphodiesterase 4D isoform 3 (PDE4D3) is a long isoform of the PDE4D enzyme family that specifically hydrolyzes the second messenger cyclic adenosine monophosphate (cAMP) [2, 3]. It is a critical regulator of intracellular cAMP levels, which orchestrates various signaling pathways involved in inflammation, cardiac function, and cognitive processes [3, 6]. PDE4D3 is uniquely regulated by phosphatidic acid and is integrated into macromolecular complexes, or signalosomes, with proteins such as the ryanodine receptor (RyR2) and SERCA2a in the heart, and AKAP9 at the centrosome [1, 7, 10]. Dysregulation or deficiency of PDE4D3 has been linked to several pathologies, including heart failure, stroke, and neurodegenerative diseases like Alzheimer's [6, 8, 10]. While PDE4 inhibitors are effective as anti-inflammatory and cognitive-enhancing agents, their clinical application is often limited by side effects such as nausea and emesis, which are partly attributed to the inhibition of PDE4D isoforms in the brain's emetic center [3, 6]. Current drug development efforts aim to create isoform-selective or allosteric inhibitors to achieve therapeutic benefits while minimizing these gastrointestinal adverse effects [6, 12].

Other names

PDE4DDPDE3STRK1HSPDE4D3cAMP-specific phosphodiesterase 4DPhosphodiesterase 4D isoform 3

Inhibition of cAMP hydrolysis, leading to increased intracellular cAMP levels and subsequent activation of PKA and Epac signaling pathways.